Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cancer drug combo targets Hard-to-Treat tumors

NCT ID NCT05155332

Terminated Disease control Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new drug, BI 1831169, given alone or with an immunotherapy (anti-PD-1 antibody) in adults with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find the highest safe dose and see if the treatment shrinks tumors. Participants receive the drug every 3 weeks for up to 3 months (alone) or up to 1 year (with immunotherapy). The trial is currently on hold.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

BI 1831169 (injected into tumor or infused into vein) and an anti-PD-1 antibody (checkpoint inhibitor, infused into vein)

What this could lead to

If it works, this could point toward a new treatment option for advanced solid tumors that are hard to treat.

What could go wrong

This is a very early (Phase 1) and small study, so the treatment may not work or may cause side effects. The trial is currently suspended, which adds uncertainty.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMORS

Contacts and locations

Locations

  • Atrium Health Wake Forest Baptist Comprehensive Cancer Center

    Winston-Salem, North Carolina, 27157, United States

  • Banner MD Anderson Cancer Center-Gilbert-55251

    Gilbert, Arizona, 85234, United States

  • CTR Eugène Marquis

    Rennes, 35042, France

  • Clínica Universidad de Navarra

    Pamplona, 31008, Spain

  • Edegem - UNIV UZ Antwerpen

    Edegem, 2650, Belgium

  • Fundación Jiménez Díaz

    Madrid, 28040, Spain

  • HOP Timone

    Marseille, 13385, France

  • Hospital Duran i Reynals

    L'Hospitalet de Llobregat, 08907, Spain

  • INS Bergonie

    Bordeaux, 33000, France

  • Institut Gustave Roussy

    Villejuif, 94805, France

  • Istituto Di Candiolo

    Candiolo (TO), 10060, Italy

  • M Health Fairview University of Minnesota Medical Center

    Minneapolis, Minnesota, 55455, United States

  • Medical University of Innsbruck

    Innsbruck, 6020, Austria

  • Morristown Medical Center

    Morristown, New Jersey, 07960, United States

  • Orlando Health Cancer Institute

    Orlando, Florida, 32806, United States

  • Peninsula Haematology & Oncology

    Frankston, Victoria, 3199, Australia

  • Princess Margaret Cancer Centre

    Toronto, Ontario, M5G 2M9, Canada

  • Providence St. John's Health Center

    Santa Monica, California, 90404, United States

  • Salzburg Cancer Research Institute

    Salzburg, 5020, Austria

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • UZ Leuven

    Leuven, 3000, Belgium

  • University Hospital Geneva

    Geneva, 1205, Switzerland

  • University of Arizona

    Tucson, Arizona, 85719, United States

  • University of California San Diego

    La Jolla, California, 92037, United States

  • University of Colorado Denver

    Aurora, Colorado, 80045, United States

  • Universitätsklinikum Tübingen

    Tübingen, 72076, Germany

  • Universitätsklinikum Ulm

    Ulm, 89081, Germany